My heart is full after getting this by email after the recent ADHDKCTeen event. It's why I do what I do. Comments shared with permission.
Creating a place where tweens and teens with ADHD feel understood, connected, and excited to come back is exactly why we started this group. adhdkc.org for more
![Graphic with a blue background and the word "Testimonial" in large white script at the top. A white note attached with a paperclip displays the ADHDKC Teen logo and a parent testimonial. A red box covers the child's name for privacy. The testimonial reads: "I want to sincerely thank you again for proceeding with this evening's event. [Child's name] told us during dinner that he wishes the next event could be tomorrow, and he asked me to register him for the group. He seems eager to see the materials provided and the website in general. So, THANK YOU again, and have a wonderful rest of your week!"](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:xitpfrpmistljpssx3i6csfd/bafkreibsac2e6hs3q5l56emwgpp55ilwxpjcnzn4e65j6rgbd2o553ksqq)
![Why Microdosing in Normal-Weight Patients Remains Unproven
Despite the mechanistic plausibility, several critical gaps prevent recommending this approach:
No dedicated trials exist. There are no completed or registered clinical trials evaluating sub-weight-loss doses of any GLP-1 RA specifically for anti-inflammatory endpoints in normal-weight individuals.
[13]
The "minimum effective anti-inflammatory dose" is unknown. While preclinical data suggest anti-inflammatory effects at sub-anorectic doses, the threshold for clinically meaningful inflammation reduction in humans has not been established. The dose-response curve for inflammation may differ substantially from that for weight loss, but this has not been characterized.
[12][14]
Even low doses cause GI side effects. Nausea, vomiting, and appetite suppression occur even during the initial titration phases (e.g., semaglutide 0.25 mg), which could still cause unwanted weight loss in a normal-weight person.
[11]
Risks may not scale linearly with dose. While some adverse effects (GI symptoms, gallbladder disease) are dose-dependent, others — such as the potential thyroid cancer signal — may be related to duration of GLP-1 receptor activation rather than dose per se, meaning even low doses over long periods could carry risk.
[11]](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:xitpfrpmistljpssx3i6csfd/bafkreif5gdemu7otnfu64zjflahuj7t4ngd7l2xehr2nkydykr7kbvtr4y)
